Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.
$HIMS
Medical/Nursing Services
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2025 | Buy → Hold | Needham | |
| 6/4/2025 | $61.00 → $65.00 | Buy | Needham |
| 4/29/2025 | $30.00 | Buy → Hold | TD Cowen |
| 2/18/2025 | $42.00 → $60.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/10/2025 | $24.00 → $25.00 | Neutral → Sell | Citigroup |
| 1/7/2025 | $35.00 | Buy | BTIG Research |
| 12/17/2024 | $42.00 | Overweight | Morgan Stanley |
| 11/14/2024 | Buy → Underperform | BofA Securities |
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. "It's never been more clear that we are delivering exactly what millions of people have been waiti
Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today released new data showing that its personalized, digital-first approach to weight loss is driving meaningful, sustainable results, laying the groundwork for lasting success. In a first-of-its-kind U.S. analysis of treatment plans, including compounded GLP-1s, customers taking a compounded GLP-1 reported losing an average of 20.9 pounds or 10.3% of initial body weight, within six months, while reporting a low rate of side effects. Just as importantly, 75% of customers remained on treatment plans in the same timeframe, a powerful signal of real-world trust and clinical success.1 This press
Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 4, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's manageme
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
Needham downgraded Hims & Hers Health from Buy to Hold
Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $65.00 from $61.00 previously
TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00
SCHEDULE 13G - Hims & Hers Health, Inc. (0001773751) (Subject)
10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire
Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne
The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.
Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. "It's never been more clear that we are delivering exactly what millions of people have been waiti
Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 4, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's manageme
Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.him